Impact of duration of response (DOR) on overall survival (OS) in patients with metastatic melanoma treated with dacarbazine (DTIC), vemurafenib (V), or cobimetinib plus vemurafenib (C plus V): a pooled analysis

被引：0
作者：
Lewis, K. [1 ]
Larkin, J. [2 ]
Ribas, A. [3 ]
Flaherty, K. T. [4 ]
McArthur, G. A. [5 ]
Ascierto, P. A. [6 ]
Dreno, B. [7 ]
McKenna, E. [8 ]
Zhu, Q. [9 ]
Mun, Y. [8 ]
Hauschild, A. [10 ]
机构：
[1] Univ Colorado, Comprehens Canc Ctr, Med, Aurora, CO USA
[2] Royal Marsden Hosp NHS Fdn Trust, Oncol, London, England
[3] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA
[4] Massachusetts Gen Hosp, Med, Boston, MA 02114 USA
[5] Peter MacCallum Canc Ctr, Dept Med Oncol, East Melbourne, Australia
[6] Ist Nazl Tumori Fdn Pascale, Canc Immunotherapy & Innovat Therapy Unit, Melanoma, Naples, Italy
[7] Nantes Univ, Dermatol, Nantes, France
[8] Genentech Inc, Prod Dev, San Francisco, CA 94080 USA
[9] Genentech Inc, Oncol, San Francisco, CA 94080 USA
[10] Univ Hosp Schleswig Holstein, Dermatol, Kiel, Germany
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1241P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] B-Raf, c-KIT, VEGFR and MGMT expression analysis in advanced melanoma (MM) patients (pts) treated with dacarbazine (DTIC) plus bevacizumab (B): Correlation with response and survival
    di Pietro, Alessandra
    Barberis, Massimo
    Manzotti, Michela
    Martinoli, Chiara
    Passoni, Claudia
    Pari, Chiara
    Mosconi, Massimo
    Cataldo, Francesco
    Gandini, Sara
    Testori, Alessandro
    Ferrucci, Pier Francesco
    CANCER RESEARCH, 2011, 71
  • [32] Overall survival (OS) with first-line atezolizumab (A) or placebo (P) in combination with vemurafenib (V) and cobimetinib (C) in BRAFV600 mutation-positive advanced melanoma: Second interim OS analysis of the phase 3 IMspire150 study.
    McArthur, Grant A.
    Gutzmer, Ralf
    Stroyakovskiy, Daniil
    Gogas, Helen
    Robert, Caroline
    Protsenko, Svetlana
    Pereira, Rodrigo Perez
    Eigentler, Thomas
    Rutkowski, Piotr
    Demidov, Lev V.
    Zhukova, Natalia V.
    Schachter, Jacob
    Yan, Yibing
    Caro, Ivor
    Hertig, Christian
    Xue, Cloris
    Kusters, Lieke
    Ascierto, Paolo Antonio
    Lewis, Karl D.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [33] Update on overall survival in COLUMBUS: A randomised phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma
    Haydon, Andrew
    Liszkay, Gabriella
    Gogas, Helen J.
    Mandala, Mario
    Arance, Ana
    Garbe, Claus
    Dummer, Reinhard
    Ascierto, Paolo A.
    Robert, Caroline
    Pickard, Michael D.
    Sandor, Victor
    Gollerkeri, Ashwin
    Flaherty, Keith T.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 171 - 172
  • [34] Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma.
    Gogas, Helen
    Ascierto, Paolo Antonio
    Flaherty, Keith
    Arance, Ana
    Mandala, Mario
    Liszkay, Gabriella
    Garbe, Claus
    Schadendorf, Dirk
    Krajsova, Ivana
    Gutzmer, Ralf
    de Groot, Jan Willem
    Dutriaux, Caroline
    Loquai, Carmen
    Gollerkeri, Ashwin
    Pickard, Michael D.
    Robert, Caroline
    Dummer, Reinhard
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [35] Impact of baseline genetic heterogeneities on progression-free survival (PFS) in patients (pts) with advanced BRAFV600-mutated melanoma treated with cobimetinib (COBI) plus vemurafenib (VEM) in the phase 3 coBRIM study
    McArthur, G.
    Larkin, J.
    Dreno, B.
    Ascierto, P.
    Liszkay, G.
    Maio, M.
    Mandala, M.
    Demidov, L.
    Stroyakovskiy, D.
    Thomas, L.
    De la Cruz-Merino, L.
    Atkinson, V.
    Dutriaux, C.
    Garbe, C.
    Wongchenko, M.
    Hsu, J.
    Koralek, D.
    Rooney, I.
    Yan, Y.
    Ribas, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S722 - S723
  • [36] Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma.
    Liszkay, Gabriella
    Gogas, Helen
    Mandala, Mario
    Fernandez, Ana Maria Arance
    Garbe, Claus
    Schadendorf, Dirk
    Dummer, Reinhard
    Ascierto, Paolo Antonio
    Robert, Caroline
    Pickard, Michael D.
    Sandor, Victor
    Gollerkeri, Ashwin
    Flaherty, Keith
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [37] Update on Overall Survival in the COLUMBUS Study: A randomized Phase 3 Study of Encorafenib (ENCO) plus Binimetinib (BINI) vs Vemurafenib (VEM) or ENCO in Patients with BRAF V600 mutated Melanoma
    Schadendorf, D.
    Garbe, C.
    Gutzmer, R.
    Loquai, C.
    Fluck, M.
    Kiecker, F.
    Mohr, P.
    Terheyden, P.
    Gogas, H. J.
    Ascierto, P. A.
    Flaherty, K. T.
    Arance, A.
    Mandala, M.
    Liszkay, G.
    Krajsova, I.
    de Groot, J. W. B.
    Dutriaux, C.
    Gollerkeri, A.
    Pickard, M. D.
    Robert, C.
    Dummer, R.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 79 - 80
  • [38] FOUR-YEAR SURVIVAL UPDATE FOR METASTATIC MELANOMA (MM) PATIENTS (PTS) TREATED WITH IPILIMUMAB (IPI) plus DACARBAZINE (DTIC) ON PHASE 3 STUDY CA184-024
    Maio, Michele
    Bondarenko, Igor
    Robert, Caroline
    Thomas, Luc
    Garbe, Claus
    Testori, Alessandro
    Francis, Stephen
    Chin, Kevin
    Wolchok, Jedd
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 : 303 - 303
  • [39] Clinical characteristics and survival of BRAF-mutant (BRAF plus ) metastatic melanoma patients (pts) treated with BRAF inhibitor (BRAFi) dabrafenib or vemurafenib beyond disease progression (PD)
    Chan, Matthew
    Haydu, Lauren
    Menzies, Alexander M.
    Azer, Mary W. F.
    Klein, Oliver
    Guminski, Alexander
    Kefford, Richard
    Long, Georgina
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [40] FOUR-YEAR SURVIVAL UPDATE FOR METASTATIC MELANOMA (MM) PATIENTS (PTS) TREATED WITH IPILIMUMAB (IPI) plus DACARBAZINE (DTIC) ON PHASE 3 STUDY CA184-024
    Maio, M.
    Bondarenko, I.
    Robert, C.
    Thomas, L.
    Garbe, C.
    Testori, A.
    Francis, S.
    Chin, K.
    Wolchok, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 367 - 367
12345